Сучасні погляди на стенокардію у пацієнтів з інтактними коронарними артеріями (INOCA)
DOI:
https://doi.org/10.37987/1997-9894.2021.2(248).229007Анотація
Представлені сучасні погляди на патофізіологічні механізми симптомів стенокардії у пацієнтів без виражених гемодинамічно значимих стенозів у коронарних артеріях. Описаний алгоритм інвазивних діагностичних тестів, які допомагають визначити ендотипи INOCA, що в подальшому відіграє важливу роль з метою призначення оптимальної медикаментозної терапії, що покращує показники якості життя у такої категорії пацієнтів.
Посилання
Global, regional, and national life expectancy, all-cause mortality, and causespecific mortality for 249 causes of death, 1980–2015: a systematic analysis for the Global Burden of Disease Study 2015 / H. Wang, M. Naghavi, C. Allen [et al.] // Lancet. – 2016. – No. 388. – Р. 1459–544. DOI: 10.1016/ s0140-6736(14)61682-2
Percutaneous coronary interventions in Europe: prevalence, numerical estimates, and projections based on data up to 2004 / S. Cook, A. Walker, O. Hugli [et al.] // Clin Res Cardiol. – 2007. – No. 96. – Р. 375–382. DOI: 10.1007/s00392-007-0513-0
Low diagnostic yield of elective coronary angiography / M. R. Patel, E. D. Peterson, D. Dai [et al.] // N. Engl. J. Med. – 2010. – No. 362. – Р. 886–895. DOI: 10.NEJMoa0907272
Stable angina pectoris with no obstructive coronary artery disease is associated with increased risks of major adverse cardiovascular events / L. Jespersen, A. Hvelplund, S. Z. Abildstrom [et al.] // Eur Heart J. – 2012. – No. 33. – Р. 734–744. DOI: 10.1093/eurheartj/ehr331
Nonobstructive coronary artery disease and risk of myocardial infarction / T. M. Maddox, M. A. Stanislawski, G. K. Grunwald [et al.] // JAMA. – 2014. – No. 312. – Р. 1754–1763. DOI: 10.1001/jama.2014.14681
Natural history of patients with insignificant coronary artery disease / R. Tavella, N. Cutri, G. Tucker [et al.] // Eur. Heart. J. Qual Care Clin Outcomes. – 2016. – No. 2. – Р. 117–124. https://doi.org/10.1093/ehjqcco/ qcv034
MINOCA: requirement for definitive diagnostic work-up / T. J. Ford, D. Corcoran, N. Sidik [et al.] // Heart. Lung. Circ. – 2019. – No. 28. – Р. 4–6. DOI: 10.1016/j.hlc.2018.04.001
Stratified medical therapy using invasive coronary function testing in angina: CorMicA trial / T.J. Ford, B. Stanley, R. Good [et al.] // J. Am. Coll. Cardiol. – 2018. – No. 72. – Р. 2841–2855. DOI: 10.1016/j.jacc.2018.09.006
Coronary microvascular function and cardiovascular risk factors in women with angina pectoris and no obstructive coronary artery disease: the iPOWER study / N. D. Mygind, M. M. Michelsen, A. Pena [et al.] // J. Am. Heart. Assoc. – 2016. – No. 5. – Р. 30–64. DOI: 10.1161/jaha.115.003064
Myocardial ischaemia in patients with coronary endothelial dysfunction: insights from body surface ECG mapping and implications for invasive evaluation of chronic chest pain / M. R. Summers, A. Lerman, R. J. Lennon [et al.] // Eur. Heart. J. – 2011. – No. 32. – Р. 2758–2765. DOI: 10.1093/eurheartj/ehr221;
Excess cardiovascular risk in women relative to men referred for coronary angiography is associated with severely impaired coronary flow reserve, not obstructivedisease / V. R. Taqueti, L. J. Shaw, N. R. Cook [et al.] // Circulation. – 2017. – No. 135. – Р. 566–577. DOI: 10.1161/circulationaha.116.023266
In women with symptoms of cardiac ischemia, nonobstructive coronary arteries, and microvascular dysfunction, angiotensinconverting enzyme inhibition is associated with improved microvascular function: A double-blind randomized study from the National Heart, Lung and Blood Institute Women’s Ischemia Syndrome Evaluation (WISE) / D. F. Pauly, B. D. Johnson, R. D. Anderson [et al.] // Am. Heart. J. – 2011. – No. 162. – Р. 678–684. DOI:10.1016/j.ahj.2011.07.011
Hoffman J. I. The myocardial oxygen supply:demand index revisited / J. I. Hoffman, G. D. Buckberg // J. Am. Heart. Assoc. – 2014. – 3. – Р. 285. DOI: 10.1161/JAHA.113.000285
Gould K. L. Coronary physiology beyond coronary flow reserve in microvascular angina: JACC state-of-theart review / K. L. Gould, N. P. Johnson // J. Am. Coll. Cardiol. – 2018. – No. 72. – Р. 2642–2662. DOI: 10.1016/j.jacc.2018.07.106
Ford T. J. Coronary artery disease: physiology and prognosis / T. J. Ford, D. Corcoran, C. Berry // Eur. Heart. J. – 2017. – No. 38. – Р. 1990–1992. DOI: 10.1093/eurheartj/ehx226
Physiological predictors of acute coronary syndromes: emerging insights from the plaque to the vulnerable patient / T. J. Ford, C. Berry, B. De Bruyne [et al.] // JACC Cardiovasc Interv. – 2017. – No. 10. – Р. 2539–2547. DOI: 10.1016/j.jcin.2017.08.059
Mechanisms of myocardial ischemia in hypertrophic cardiomyopathy: insights from wave intensity analysis and magnetic resonance / C. E. Raphael, R. Cooper, K. H. Parker [et al.] // J. Am. Coll. Cardiol. – 2016. – No. 68. – Р. 1651–1660. DOI: 10.1016/j.jacc.2016.07.751
Coronary microvascular dysfunction as a mechanism of angina in severe as: prospective adenosine-stress CMR study / J. H. Ahn, S. M. Kim, S. J. Park [et al.] // J. Am. Coll. Cardiol. – 2016. – No. 67. – Р. 1412–1422. DOI: 10.1016/j.jacc.2016.01.013
Gould K. L. Imaging coronary blood flow in AS: let the data talk, again / K. L. Gould, N. P. Johnson // J. Am. Coll. Cardiol. – 2016. – No. 67. – Р. 1423–1426. DOI: 10.1016/j.jacc.2016.01.053
Ford T. J. Stable coronary syndromes: pathophysiology, diagnostic advances and therapeutic need / T. J. Ford, D. Corcoran, C. Berry // Heart. – 2018. – No. 104. – Р. 284–292. DOI: 10.1136/ heartjnl-2017-311446
Taqueti V. R. Coronary microvascular disease pathogenic mechanisms and therapeutic options / V. R. Taqueti, M. F. Di Carli // J. Am. Coll. Cardiol. – 2018. – No. 72. – Р. 2625–2641. DOI: 10.1016/j.jacc.2018.09.042
Comparison of different diastolic resting indexes to iFR: are they all equal? / M. Van’t Veer, N. Pijls, B. Hennigan [et al.] // J. Am. Coll. Cardiol. – 2017. – No. 70. – Р. 3088–3096. DOI: 10.1016/j. jacc.2017.10.066
Effects of sex on coronary microvascular dysfunction and cardiac outcomes / V. L. Murthy, M. Naya, V. R. Taqueti [et al.] // Circulation. – 2014. – No. 129. – Р. 2518–2527. DOI: 10.1161/CIRCULATIONAHA.113.008507
Invasive evaluation of patients with angina in the absence of obstructive coronary artery disease / B. K. Lee, H. S. Lim, W. F. Fearon [et al.] // Circulation. – 2015. – No. 131. – Р. 1054–1060. DOI: 10.1161/circulationaha.114.012636
Dopplerderived intracoronary physiology indices predict the occurrence of microvascular injury and microvascular perfusion deficits after angiographically successfulprimary percutaneous coronary intervention / P. F. Teunissen, G. A. de Waard, M. R. Hollander [et al.] // Circ. Cardiovasc. Interv. – 2015. – No. 8. – Р. 1786. DOI: 10.1161/circinterventions.114.001786
Sueda S. Overview of the acetylcholine spasm provocation test / S. Sueda, H. Kohno, T. Ochi // Clin. Cardiol. – 2015. – No. 38. – Р. 430–438. DOI: 10.1002/clc.22403
Long-term follow-up of patients with mild coronary artery disease and endothelial dysfunction / J.A. Suwaidi, S. Hamasaki, S. T. Higano [et al.] // Circulation. – 2000. – No. 101. – Р. 948–954. DOI: 10.1161/01.cir.101.9.948
Prevalence of coronary microvascular dysfunction among patients with chest pain and nonobstructive coronary artery disease / J. D. Sara, R. J. Widmer, Y. Matsuzawa [et al.] // JACC Cardiovasc Interv. – 2015. – No. 8. – Р. 1445–1453. DOI: 10.1016/j.jcin.2015.06.017
Rationale and design of the British Heart Foundation (BHF) Coronary Microvascular Angina (CorMicA) stratified medicine clinical trial / T. J. Ford, D. Corcoran, K. G. Oldroyd [et al.] // Am. Heart. J. – 2018. – No. 201. – Р. 86–94. DOI: 10.1016/j.ahj.2018.03.010
International standardization of diagnostic criteria for vasospastic angina / J. F. Beltrame, F. Crea, J. C. Kaski [et al.] // Eur Heart J. – 2017. – No. 38. – Р. 2565–2568. DOI: 10.1093/eurheartj/ehv351
Coronary Vasomotion Disorders International Study Group (COVADIS). International standardization of diagnostic criteria for microvascular angina / P. Ong, P. G. Camici, J. F. Beltrame [et al.] // Int. J. Cardiol. – 2018. – No. 250. – Р. 16–20. DOI: 10.1016/j.ijcard.2017.08.068
Chan P. S. Development and validation of a short version of the Seattle angina questionnaire / P. S. Chan, P. G. Jones, S. A. Arnold // Circ. Cardiovasc. Qual. Outcomes. – 2014. – No. 7. – Р. 640–647. DOI: 10.1161/circoutcomes.114.000967
Kirtane A. J. ORBITA 2 / A. J. Kirtane // Circulation. – 2018. – No. 138. – Р. 1793–1796. DOI: 10.1161/CIRCULATIONAHA.118.035331
The parallel tales of microvascular angina and heart failure with preserved ejection fraction: a paradigm shift / F. Crea, Merz C. N. Bairey, J. F. Beltrame [et al.] // Eur. Heart. J. – 2017. – No. 38. – Р. 473–477. DOI: 10.1093/eurheartj/ehw461
ESC guidelines on the management of chronic coronary syndrome / Task Force Members, G. Montalescot, U. Sechtem [et al.] // Eur. Heart. J. – 2019. – No. 34. – Р. 2949–3003. DOI: 10.1093/eurheartj/eht296
Cholesterol lowering with pravastatin improves resistance artery endothelial function: report of six subjects with normal coronary arteriograms / J. L. Houghton, T. A. Pearson, R. G. Reed [et al.] // Chest. – 2000. – No. 118. – Р. 756–760. DOI: 10.1378/chest.118.3.756
Lack of effect of nitrates on exercise stress test results in patients with microvascular angina / G. Russo, A. Di Franco, P. Lamendola [et al.] // Cardiovasc. Drugs. Ther. – 2013. – No. 27. – Р. 229–234. DOI: 10.1007/s10557-013-6439-z
Beltrame J. F. Why do nitrates have limited efficacy in coronary microvessels? / J. F. Beltrame, J. D. Horowitz // Cardiovasc. Drugs. Ther. – 2013. – No. 27. – Р. 187–188. DOI: 10.1007/s10557-013-6454-0
Gould K. L. Nitroglycerine and angina: evolving clinical coronary physiology beyond fractional flow reserve and coronary flow reserve / K. L. Gould, N. P. Johnson // Circulation. – 2017. – No. 136. – Р. 35–38. DOI: 10.1161/circulationaha.117.028791
Isosorbide mononitrate in heart failure with preserved ejection fraction / M. M. Redfield, K. J. Anstrom, J. A. Levine [et al.] // N. Engl. J. Med. – 2015. – No. 373. – Р. 2314–2324. DOI: 10.1056/NEJMoa1510774
Ranolazine in symptomatic diabetic patients without obstructive coronary artery disease: impact on microvascular and diastolic function / N. R. Shah, M. K. Cheezum, V. Veeranna [et al.] // J. Am. Heart. Assoc. – 2017. – No. 6. – 5027. DOI: 10.1161/jaha.116.005027
A randomized, placebo-controlled trial of late Na current inhibition (ranolazine) in coronary microvascular dysfunction (CMD): impact on angina and myocardial perfusion reserve / C. N. Bairey Merz, E. M. Handberg, C. L. Shufelt [et al.] // Eur. Heart. J. – 2016. – No. 37. – Р. 1504–1513. DOI: 10.1093/eurheartj/ehv647
Rationale and design of the Coronary Microvascular Angina Cardiac Magnetic Resonance Imaging (CorCMR) diagnostic study: the CorMicA CMR substudy / D. Corcoran, T.J. Ford, L-Y. Hsu [et al.] // Open Heart. – 2018. – No. 5. – Р. 924. DOI: 10.1136/openhrt-2018-000924
Prognostic effects of calcium channel blockers in patients with vasospastic angina – a meta-analysis / K. Nishigaki, Y. Inoue, Y. Yamanouchi [et al.] // Circ. J. – 2010. – No. 74. – Р. 1943–1950. DOI: 10.1253/circj.cj-10-0292
Eosinophilic coronary periarteritis (vasospastic angina and sudden death), a new type of coronary arteritis: report of seven autopsy cases and a review of the literature / H. Kajihara, Y. Tachiyama, T. Hirose [et al.] // Virchows. Arch. – 2013. – No. 462. – P. 239–48. DOI: 10.1007/s00428-012-1351-7
Coronary microvascular dysfunction and future risk of heart failure with preserved ejection fraction / V. R. Taqueti, S. D. Solomon, A. M. Shah [et al.] // Eur. Heart. J. – 2018. – No. 39. – P. 840–9. DOI: 10.1093/eurheartj/ehx721
